Randomized multicentre pilot study of LCZ696 versus irbesartan in patients with chronic kidney disease: UK Heart And Renal Protection (HARP)-III
Phase of Trial: Phase II
Latest Information Update: 31 Mar 2017
At a glance
- Drugs Sacubitril/valsartan (Primary) ; Irbesartan
- Indications Renal failure
- Focus Therapeutic Use
- Acronyms UK HARP-III
- Sponsors Novartis
- 19 Sep 2016 Trial rationale, trial design and baseline data (n=414) published in the Nephrology Dialysis Transplantation.
- 04 Mar 2016 Status changed from recruiting to active, no longer recruiting as per United Kingdom Clinical Research Network record.
- 04 Mar 2016 Planned number of patients changed from 360 to 400 as per United Kingdom Clinical Research Network record.